文献速递神经肿瘤

胶质母细胞瘤富集的鞘糖脂调节人iNKT细胞功能

Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究用液相色谱-质谱检测胶质母细胞瘤干样细胞、低级别胶质瘤细胞和正常人星形胶质细胞的脂质水平,发现多种硫苷脂在胶质母细胞瘤干样细胞中独特富集。这些硫苷脂经CD1d呈递后以剂量依赖方式激活iNKT细胞,而溶血硫苷脂抑制iNKT细胞活化及α-半乳糖神经酰胺诱导的活化。作者认为胶质母细胞瘤干样细胞富集的鞘糖脂对iNKT细胞功能的调节可能促进胶质母细胞瘤免疫抑制,并提示硫苷脂生成是潜在治疗靶点。

要点

  • 多种硫苷脂在胶质母细胞瘤干样细胞中独特富集。
  • 硫苷脂经CD1d呈递以剂量依赖方式激活iNKT细胞。
  • 溶血硫苷脂抑制iNKT细胞活化及α-半乳糖神经酰胺诱导的活化。

核心结论

  • 胶质母细胞瘤干样细胞富集的鞘糖脂对iNKT细胞功能的调节可能促进胶质母细胞瘤的免疫抑制,并提示硫苷脂生成是胶质母细胞瘤治疗的潜在靶点。

研究设计与样本

  • 研究用液相色谱-质谱测定多种人胶质母细胞瘤干样细胞系、低级别胶质瘤细胞系和正常人星形胶质细胞的脂质水平,并用胶质母细胞瘤干样细胞富集的脂质在人iNKT细胞系及健康供者和胶质母细胞瘤患者的PBMC样本中进行iNKT刺激试验。

主要发现

  • 多种脂质在胶质母细胞瘤干样细胞中独特富集,其中许多为硫苷脂,经CD1d呈递后可被iNKT细胞识别并以剂量依赖方式激活iNKT细胞。
  • 在胶质母细胞瘤干样细胞内对硫苷脂合成途径进行药物和遗传靶向,可改变其激活iNKT细胞的能力。
  • 溶血硫苷脂抑制iNKT细胞活化,并抑制α-半乳糖神经酰胺诱导的活化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To develop effective therapies for glioblastoma (GBM), a deeper understanding of its underlying immunoregulatory mechanisms is needed. Invariant natural killer T (iNKT) cells are unconventional T cells that recognize lipid antigens and are known to regulate tumor immunity in other cancer types. Given the lipid-rich nature of the brain and the unique metabolic activity of GBM cells, we hypothesized that GBM-enriched lipids could direct iNKT cells to contribute to the immunosuppressive nature of the disease. METHODS: Lipid levels of multiple human GBM stem-like cell (GSC) lines, low grade-glioma lines, and normal human astrocytes were determined using liquid-chromatography mass spectrometry. GBM stem-like cell-enriched lipids were tested in iNKT stimulation assays, with either human iNKT cell lines or PBMC samples from both healthy donors and GBM patients, to determine antigenicity and characterize the nature of iNKT activation. RESULTS: Multiple lipid species were found to be uniquely enriched in GSCs. Many of these lipids, called sulfatides, were recognized by and activated iNKT cells in a dose-dependent manner when presented by CD1d. Pharmaceutical and genetic targeting of the sulfatide synthetic pathway within GSCs resulted in an altered ability to activate iNKT cells. However, one lipid, lyso-sulfatide, inhibited the activation of iNKT cells and suppressed activation induced by a cognate antigen, α-galactosylceramide. CONCLUSIONS: The modulation of iNKT cell functions by GSC-enriched glycosphingolipids may contribute to the immunosuppression of GBM and highlights sulfatide production as a potential therapeutic target for GBM treatment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Coombs MJ, Dowdy T, Alam MM, et al. Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells. Neuro Oncol. 2025. PMID: 40435375. doi:10.1093/neuonc/noaf135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。